Focus on migraine prodrome: what should clinicians know?

PURPOSE OF REVIEW: The prodromal phase of migraine is highly prevalent and can be very disabling. In this review, we seek to understand the clinical features of prodrome and its underlying pathophysiology. Our aim is to assess the impact of early treatment of migraine during the prodromal phase.

RECENT FINDINGS: A recent phase 3 trial showed ubrogepant is effective at preventing migraine during the prodromal phase. Further studies have shown it is effective in reducing disabling symptoms of the prodrome itself and positive patient reported outcomes.

SUMMARY: The prodromal phase of migraine presents the earliest opportunity to treat migraine and prevent disability. Studies have shown that the use of medications during this phase of migraine to be effective with recent studies showing ubrogepant is effective when used during prodrome.